Bhatia Rinky, Hare Joshua M
Department of Medicine, Division of Cardiology and Institute for Cell Engineering (ICE), Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Congest Heart Fail. 2005 Mar-Apr;11(2):87-91; quiz 92-3. doi: 10.1111/j.1527-5299.2005.03618.x.
Current treatments for ischemic cardiomyopathy are aimed toward minimizing the deleterious consequences of damaged myocardium. The possibility of treating heart failure by generating new myocardium and vascular structures has provided major impetus for recent stem cell research. Mesenchymal stem cells (MSCs), also referred to as marrow stromal cells, differentiate into a wide variety of lineages, including myocardial smooth muscle and possibly endothelial cells. The multilineage potential of MSCs, their ability to elude detection by the host's immune system, and their relative ease of expansion in culture make MSCs a very promising source of stem cells for transplantation. This paper reviews animal and human trials studying the role of MSCs in cardiomyogenesis and vasculogenesis in postinfarct myocardium, factors that stimulate MSC differentiation, routes of MSC delivery, and methods of detecting MSC engraftment.
目前针对缺血性心肌病的治疗旨在将受损心肌的有害后果降至最低。通过生成新的心肌和血管结构来治疗心力衰竭的可能性为近期的干细胞研究提供了主要动力。间充质干细胞（MSCs），也被称为骨髓基质细胞，可分化为多种谱系，包括心肌平滑肌细胞以及可能的内皮细胞。MSCs的多谱系潜能、逃避宿主免疫系统检测的能力以及在培养中相对容易扩增的特性，使得MSCs成为用于移植的非常有前景的干细胞来源。本文综述了研究MSCs在梗死心肌的心肌生成和血管生成中的作用、刺激MSCs分化的因素、MSCs的递送途径以及检测MSCs植入的方法的动物和人体试验。
